VANGUARD GROUP INC 13D and 13G filings for Reata Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-09 11:30 am Purchase |
2022-12-30 | 13G | Reata Pharmaceuticals, Inc. RETA |
VANGUARD GROUP INC | 2,705,656 8.530% |
147,983 (+5.79%) |
Filing |
| 2022-02-10 08:32 am Purchase |
2021-12-31 | 13G | Reata Pharmaceuticals, Inc. RETA |
VANGUARD GROUP INC | 2,557,673 8.130% |
237,642 (+10.24%) |
Filing |
| 2021-02-10 11:47 am Purchase |
2020-12-31 | 13G | Reata Pharmaceuticals, Inc. RETA |
VANGUARD GROUP INC | 2,320,031 7.470% |
153,145 (+7.07%) |
Filing |